CluePoints wins European Venture Contest award

Thursday, December 11, 2014

CluePoints, a Cambridge, Mass.-based provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has won a European Venture Contest award. The award program, which is part of the European Venture Summit, acknowledged CluePoints for its Central Statistical Monitoring (CSM) solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data. The win represents the second industry award that CluePoints has secured this month after the company’s risk-based monitoring solution also was recognized by the Scrip Awards.

[Read More]

Report: Type 2 diabetes population to expand in China

Wednesday, December 10, 2014

For the treatment of type 2 diabetes in China, patient access to premium-priced agents is impeded as not all patients can afford these drugs, Burlington, Mass.-based Decision Resources Group has found. The National Reimbursement Drug List was last updated in 2009, and several antidiabetic drug classes (e.g. DPP-IV inhibitors and GLP-1 receptor agonist) are not covered, as they were only approved for use in China after 2009.

[Read More]

Accovion launches new subsidiary in France

Monday, December 1, 2014

Accovion, an independent, European, full-service CRO headquartered in Frankfurt, Germany, has established a new subsidiary in Lyon, France, as it continues its expansion across Europe. Together with offices in Italy, Poland, Russia, Romania, Spain, Czech Republic and the U.K., Accovion now is able to present itself with eight subsidiaries and overall coverage of 20 European countries.

[Read More]

EMA revises policy on conflicts of interest

Friday, November 21, 2014

The EMA has published its revised policy on handling declarations of interests for scientific committee members and experts. The revisions reflect a more balanced approach to handling conflicts of interests that aims to effectively restrict the involvement of experts with possible conflicts of interests in the agency’s work, while maintaining EMA’s ability to access the best available expertise.

[Read More]

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

[Read More]